Company news

Eton Pharmaceuticals, Inc. news in 2026

Eton Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results

November 5, 2026

Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability

November 5, 2026

Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London

November 4, 2026

Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms

November 2, 2026

Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

October 29, 2026

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

October 14, 2026

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

September 28, 2026

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

August 27, 2026

Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 13, 2026

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

August 5, 2026

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

August 3, 2026

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI Oral Solution

July 30, 2026

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

July 29, 2026

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

May 18, 2026

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

May 14, 2026

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026

Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

May 4, 2026

Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution

May 1, 2026

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

April 27, 2026

Eton Pharmaceuticals Announces CFO Succession Plan

April 15, 2026

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

March 18, 2026

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

March 3, 2026

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

March 2, 2026

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

February 25, 2026

Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

February 20, 2026

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

February 2, 2026

Calls in 2026

Decks in 2026